The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...
Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances ...
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President ...
Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through ...
Hosted on MSN
Certara appoints Jon Resnick as new CEO
Certara ( (CERT)) has provided an update. On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment of Jon Resnick as the new Chief Executive Officer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback